去甲氧柔红霉素治疗急性髓细胞性白血病临床观察

Clinical observation of treatment of acute myeloid leukemia with idarubicin

摘要: 目的:观察以去甲氧柔红霉素(IDA)为主的化疗方案治疗急性髓细胞性白血病(AML)的疗效和不良反应。方法:39例AML患者,随机分为2组。对照组16例采用柔红霉素+阿糖胞苷(Ara-C)治疗,治疗组23例采用IDA+Ara-C治疗,观察治疗后缓解率及不良反应。结果:2组治疗完全缓解率分别为82.6%和43.8%,总有效率分别为91.3%和62.5%,临床严重感染率分别为40.0%和41.7%。2组总有效率差异有统计学意义(P0.05),但2组的严重感染发生率差异无统计学意义(P0.05)。结论:以IDA组成的联合化疗方案治疗AML疗效较好。

Abstract: Objective: To investigate the clinical effects and toxic reaction of idarubicin(IDA) on the acute myeloid leukemia(AML) .Methods: Thirty-nine patients with AML were randomly divided into treatment group，which were treated with IDA and Ara-C(23 cases) and control group which were treated with daunorubicin combined with Ara-C(16 cases) .The remission rates and toxic reaction of two groups were observed.Results: The complete remission， total effective and severe infection rates of the treatment and control group were 82.6%and 43.8%， 91.3% and 62.5% and 40.0% and 41.7%， respectively.The difference of total effective of two groups was statistical significant(P0.05) ，but for not severe infection rates(P0.05) .Conclusions: The effects of treatment of AML with chemotherapeutic scheme containing IDA are good.